MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Vericel Corporation DSO Ratio 2011-2026 | VCEL
Annual DSO Ratio Vericel Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.5 | 92.1 | 96.9 | 93.2 | 84.1 | 98 | 99.6 | 94.2 | 104 | 115 | 77.9 | 104 | - | 487 | 182 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 487 | 77.9 | 130 |
Quarterly DSO Ratio Vericel Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88.6 | 84.3 | 84.5 | 99.1 | - | 76 | 84.8 | 96.3 | - | 78.1 | 76.2 | 94.4 | - | 40.6 | 39.2 | 87.6 | - | 80.2 | 70.3 | 84 | 69.6 | 97.6 | 157 | 114 | 74.5 | 96.2 | 112 | 116 | 68.3 | 95.2 | 113 | 106 | 71.4 | 117 | 98.3 | 172 | 94.4 | 143 | 122 | 90.6 | 64.6 | 88.1 | 73.3 | 80.4 | 50.8 | 77.4 | 169 | - | - | - | 122 | 160 | 88.8 | 411 | 456 | 456 | - | 91.2 | 91.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 456 | 39.2 | 115 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
29 | - | 1.35 % | $ 17.8 M |  China |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.09 | -6.08 % | $ 195 M |  Israel |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.47 | -6.67 % | $ 172 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 51.42 | -9.71 % | $ 4.62 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 28.65 | -4.29 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
2.16 K | - | - | $ 13.1 M | Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
76.5 | $ 14.54 | -1.72 % | $ 208 M | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.12 | -1.27 % | $ 5.14 M | Israel |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 21.51 | -2.0 % | $ 2.74 B | USA |